血甲基氨酸和在缺血性中风后的认知障碍
Jiawen Fei1, Xinyue Chang1, Wenjing Yang2
1Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Journal of the American Heart Association
|September 19, 2025
概括
血液中的高基胺水平与在三个月内发生中风后认知障碍 (PSCI) 的风险更高有关. 这一发现表明,甲基胺可能作为中风患者PSCI的预测生物标志物.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 脑卒中研究 脑卒中研究
背景情况:
- 乙谷氨 (PAG) 与缺血性中风和一般认知表现有关.
- PAG水平和中风后认知障碍 (PSCI) 之间的特定关系在很大程度上仍未得到研究.
- 需要进行前性调查以澄清这种关联.
研究的目的:
- 为了前性地研究血甲基胺水平与在中风后3个月患PSCI的风险之间的关联.
- 确定PAG是否可以作为PSCI的预测生物标志物.
主要方法:
- 分析了来自CATIS研究的617名缺血性中风患者队列.
- 脑卒中后认知障碍 (PSCI) 在3个月后使用小型精神状态检查 (MMSE) 和蒙特利尔认知评估 (MoCA) 尺度进行评估.
- 使用后勤回归和脊柱回归模型分析了血PAG水平和PSCI风险之间的关联,并根据相关的共变量进行调整.
主要成果:
- 376名参与者 (61%) 根据MMSE得分在3个月后发展出PSCI.
- 在多变量调整后,较高的血甲基胺水平与最高三位数相比较低的PSCI (OR=2.16;95% CI,1.32-3.54) 的几率增加显著相关.
- 在血PAG水平和PSCI风险 (P为线性<0.001) 之间观察到正线性关联,PAG改善了PSCI风险重新分类.
结论:
- 高血甲基胺水平显着与3个月后发展中风后认知障碍 (PSCI) 的风险增加有关.
- 氨基胺在血中显示出作为预测生物标志物的潜力,用于识别在缺血性中风后患PSCI风险较高的患者.
- 进一步的研究可能会验证PAG作为PSCI风险分层的临床工具.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


